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Summary 
 
Background: The tumor cell proliferation and progression of breast cancer are markedly 
influenced by female sex steroids, especially estradiol or E2. Aromatase inhibitors (AIs) are 
generally considered a gold standard for the neoadjuvant endocrine therapy of the estrogen 
receptor (ER) positive postmenopausal breast cancer patients. However, the resistance and 
disease progression inevitably occur among some of these patients receiving AIs therapy. These 
phenomena are considered to be at least partly due to an emergence of alternative intratumoral 
estrogen and/or androgen production pathways which are under the influence of many 
intratumoral enzymes. The mechanisms underlying these estrogenic and/or androgenic enzymes 
actions following the neoadjuvant endocrine therapy for the postmenopausal breast cancer 
patients have, however, remained relatively unknown. It has thus become important to evaluate 
the alterations of intratumoral estrogenic and androgenic enzymes in order to provide clear 
insights into how the ER positive breast carcinoma tissues develop into a state of resistance 
towards AIs, but the study of the changes of these enzymes before and after AIs treatment has 
not necessarily been clarified, to the best of my knowledge. 
 
Material and Methods: I first evaluated the alterations of the enzymes involved in intratumoral 
estrogen production including steroid or estrogen sulfatase (STS), 17β-hydroxysteroid 
dehydrogenase type 1 (17βHSD1) and estrogen sulfotransferase (EST) in the breast cancer 
tissues before and after the neoadjuvant exemestane (EXE) treatment of the JFMC34-0601 trial 
study using immunohistochemistry (IHC) in order to examine the alteration of these enzymes 
after AIs treatment in 49 cases in my present study. I then correlated the findings with the 
therapeutic responses of individual patients, including clinical and pathological responses, and 
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alterations of Ki67 before and after the therapy of individual patients as well as with the changes 
of ER, progesterone receptor (PgR), and human epidermal growth factor receptor type 2 (Her2) 
in breast cancer patients, in order to further study the correlation of these findings with AIs 
response or resistance in individual patients. It is important to study not only the alterations of 
intratumoral estrogenic enzymes but also those of androgenic enzymes which play pivotal roles 
in the breast carcinoma cells following AIs treatment, as mentioned above, in order to study the 
alterations of intratumoral hormonal microenvironment in breast cancer tissues following AIs 
treatment. Therefore, I also used IHC to evaluate the alterations of androgenic enzymes, 
including 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5), 5α-reductase type 1 (5αRed1), 
and 5α-reductase type 2 (5αRed2) as well as androgen receptor (AR) expression in breast cancer  
tissues of the CAAN trial study which consisted of the pre- and post-AIs treatment specimens of 
29 cases. I subsequently correlated the findings with the alteration of Ki67 in breast carcinoma 
tissues as well as the changes of ER, PgR, and Her2 of individual patients, before and after the 
therapy, in order to further evaluate these changes of intratumoral androgen producing pathways 
which may or may not be correlated with the estrogen producing pathways.  I subsequently 
examined the clinical and biological significance of intratumoral androgenic enzymes, especially 
5αRed2, in association with the decreased Ki67 from estrogen depletion caused by AIs therapy 
in order to study the alteration of these enzymes in the AIs response group.  
 
Results:  In the first study on intratumoral estrogenic enzymes, the pre-treatment specimens of 
the JFMC34-0601 study demonstrated the following features: ER positive, PgR positive, and 
HER2 positive (100%, 85.7%, and 77.6%, respectively). However, following the treatment, the 
number of Ki67, PgR, and ER positive carcinoma cells was associated with significant 
decrement in number, especially in both clinical and pathological response groups. In addition, I 
detected the significant increment of 17βHSD1 and STS immunoreactivity in all examined 
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groups except for STS in pathological response group. In contrast to these findings above, EST 
demonstrated significant increment in clinical and pathological non-response groups. I also 
detected the significant alterations of intratumoral enzymes following the EXE neoadjuvant 
treatment, in particular, the increment of 17βHSD1 and STS following the therapy was 
significantly correlated with the Ki67 reduction (p-value = 0.0003, and p-value = 0.0008, 
respectively). 
  In the second study on intratumoral androgenic enzymes, results of the CAAN trial study 
demonstrated significant increment of both 5αRed2 and AR (p-value = 0.025, and p-value = 
0.039, respectively) in the pathological/biological response group whose Ki67 was decreased by 
more than 40% of the pre-treatment level.  
 
Conclusion: My present study is the first to demonstrate the significant increment of 
intratumoral estrogenic enzymes; 17βHSD1 and STS, and androgenic enzymes; 5αRed2 as well 
as its receptor; AR, following AIs therapy.  These parameters were all significantly correlated 
with Ki67 reduction following the neoadjuvant AIs treatment for the postmenopausal ER 
positive breast cancer patients. Results of my present study clearly demonstrated the following 
novel findings: (1) the increment of intratumoral estrogenic enzymes; 17βHSD1 and STS, 
represents at least one of the mechanisms for the development of resistance to AIs treatment in 
hormonal-dependent breast carcinoma cells, (2) the increment of intratumoral androgenic 
enzymes; 5αRed2, and androgen receptor partly contributes to inhibition of the breast carcinoma 
cell proliferation through increasing androgenic actions to carcinoma cells, and (3) the 
alterations of the androgenic enzymes, especially a de novo increment of 5αRed2 as well as AR 
following the AIs treatment are indeed considered at least one of the mechanisms which account 
for the decreased breast carcinoma cells proliferation. However, the regulatory mechanisms of 
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5αRed2 in human breast cancer have remained largely unknown and it awaits further 
investigations for clarification. 
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Abbreviations used in this thesis 
AIs                               aromatase inhibitors 
ANA                                anastrozole 
AR                                   androgen receptor 
CAAN                             Celecoxib Anti-aromatase Neoadjuvant 
COX-2                             cyclooxygenase 2 
CR                                   complete response 
DAB                                3, 3’-diaminobenzidine 
DHEA                              dehydroepiandrosterone 
DHEAS                           dehydroepiandrosterone sulfate 
DHT                                5α-Dihydrotestosterone 
ER                                   estrogen receptor    
EST                                 estrogen sulfotransferase 
E1                                    estrone 
E2                                    estradiol 
EXE                                 exemestane 
FSH                                 follicle-stimulating hormone 
Her2                                 human epidermal growth factor receptor type 2 
H2O2                                 hydrogen peroxide 
17βHSD1                         17β-hydroxysteroid dehydrogenase type 1 
17βHSD2                         17β-hydroxysteroid dehydrogenase type 2 
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17βHSD5                         17β-hydroxysteroid dehydrogenase type 5 
IHC                                  immunohistochemistry 
Ki 67                                 Ki 67 protein 
LET                                  letrozole 
LI                                     labeling index 
mg                                    milligram 
PD                                    progressive disease 
PgR                                  progesterone receptor 
PR                                    partial response 
5αRed1                             5α-reductase type 1 
5αRed 2                            5α-reductase type 2 
SD                                    stable disease 
STS                                  steroid or estrogen sulfatase 
µm                                    micrometer 
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Chapter 1 
Introduction 
 
1.1 Introduction 
Breast cancer is the most common malignancy among women worldwide and is recognized 
as one of the leading causes of cancer death among females, accounting for 23% of the total cancer 
cases and 14% of the cancer death [1, 2]. It has been well accepted that breast cancer is a 
hormonal-dependent malignancy in approximately 60% of premenopausal and 75% of 
postmenopausal patients [3, 4]. The sex-steroid hormones, particularly estrogens, play a pivotal 
role in the proliferation, survival and metastasis of breast carcinoma cells through binding with 
estrogen receptor (ER) located within their nuclei. By contrast, androgens exert opposing effects 
upon the growth and development of breast carcinoma cells as well as antiproliferative effects via 
androgen receptor (AR) [5, 6]. Yet there have been some controversies as to those above [7]. The 
physiological and pathological interplay between estrogens and androgens in various endocrine 
target organs including the breast is well recognized [8]. In addition, estrogens and androgens have 
both been reported to be locally produced in breast cancer tissues in an intracrine manner [9, 10]. 
Therefore, the interaction and interplay between these sex steroids in the breast cancer tissue 
should be assessed and carefully examined. In addition, results of my present study should explain 
two important questions: 1) how the breast carcinoma cells can survive under the estrogen 
depletion environment, 2) what are the actual mechanisms behind the resistance of breast 
carcinoma cells to the aromatase inhibitors (AIs), the new target therapy. I do hope that my present 
study will eventually lead to the overcoming of clinical resistance to endocrine therapy, the most 
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patient-friendly treatment, and to the status of “living with cancer for life” in ER positive breast 
cancer patients. 
 
1.2 Estrogens and breast cancer 
Estrogens are a group of steroid hormones that are essential for the proper functions, 
maturation and maintenance of normal female physiology and reproduction. Among these sex 
steroids, estrogens, especially estradiol or E2, a biologically potent estrogen, play pivotal roles in 
cell proliferation, development and invasion of these hormone-dependent breast carcinoma cells 
and also represent a significant factor in the breast cancer carcinogenesis as well [3, 4, 11]. 
Intratumoral estrogen production in breast cancer tissues was first documented by the 
group of Miller in 1974 [12].  Its clinical significance was originally in dispute, but the presence of 
local production of estrogens in breast carcinoma tissues has been subsequently reported by others 
including the group of Sasano [13-16]. E2 originates from different sources of the body before and 
after menopause in women. While the primary source of circulating estrogens in pre-menopausal 
women is detected in the ovaries or granulosa cells of dominant follicles. However, the secretion 
of E2 by the ovaries ceases after menopause, and then estrogens are produced principally in 
various peripheral tissues including skin, muscle, fat, bone, and others [11]. After menopause, all 
estrogens and almost all androgens are locally synthesized in the peripheral tissues through 
conversion of the circulating inactive precursor steroids dehydroepiandrosterone (DHEA) and 
DHEA sulfate (DHEAS) of adrenal gland [11]. 
Human breast cancer tissues contain various steroidogenic and metabolizing enzymes 
which are involved in E2 and androgens bioformation [3, 6, 8-11]. Aromatase, one of the enzymes 
involved in estrogen production, was subsequently demonstrated in adipocytes, stro 
mal cells and carcinoma cells of breast cancer tissues [15-19]. In addition, the other 
enzymes involved in intratumoral estrogen production (steroid or estrogen sulfatase, STS; estrogen 
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sulfotransferase, EST; and 17β-hydroxysteroid dehydrogenase type 1, 17βHSD1 and so on) have 
also been reported to be overexpressed in human breast carcinoma tissues by a number of 
laboratories including that of Sasano [16, 18, 20, 21] (Figure 1).  
Among these enzymes above, aromatase is the one catalyzing the rate limiting step in the 
biosynthetic pathway for estrogens [22] and has been considered an important critical target for 
pharmacological inhibitors which may cause estrogen deprivation in the postmenopausal patients 
with ER-positive breast carcinoma [3, 19, 21]. The introduction of AIs in the treatment algorithms 
of these breast cancer patients has been actually considered one of the major or pivotal 
achievements in breast cancer therapy throughout the past decades [23, 24]. AIs produce a state of 
estrogen deprivation through an inhibition of aromatase that converts androgens into estrone (E1) 
or E2, in the peripheral tissues as well as within the breast carcinoma cells. Especially, third-
generation AIs suppress the aromatase activity in the magnitudes of more than 98%, which 
subsequently resulted in clinical benefits and relatively lower incidences of adverse effects [22, 
25]. This relatively patient-friendly therapy has been established as the gold standard of endocrine 
therapy for all stages of ER positive postmenopausal breast cancer patients in numerous countries 
including Japan.  
 
1.3 Androgens and breast cancer 
As described above, the breast carcinoma cells are not only empowered and influenced by 
estrogens, but also by androgens that interplay pivotal roles in the intratumoral hormonal 
microenvironment. Androgen receptor (AR) is commonly expressed in human breast cancer 
tissues [26]. The well established data of in situ production of androgens and the presence of AR 
in breast carcinoma cells also indicate potentially important roles for androgens in breast cancers 
[5-7, 9]. In particular, androgen producing enzymes, such as: 17β-hydroxysteroid dehydrogenase 
type 5 (17βHSD5; conversion from circulating androstenedione and then into testosterone) and 5α-
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reductase type 1 and type 2 (5αRed1 and 5αRed2, respectively; reduction of testosterone to 5α-
Dihydrotestosterone (DHT)), have been reported to be abundantly expressed, and locally produced 
in the breast carcinoma tissues [8, 27]. This in situ produced DHT then binds with the highest 
affinity to AR and promotes AR transcriptional activity [8] (Figure 1).   
 The group of Sasano has previously demonstrated an association between the status of 
intratumoral androgenic enzymes, 5αRed1, and DHT concentration in the breast cancer tissue, and 
an inverse correlation between intratumoral DHT concentration and aromatase expression in cell 
culture experiments [27]. In addition, the same group has also recently demonstrated the increment 
of intratumoral DHT concentration and 17β-hydroxysteroid dehydrogenase type 2 (17βHSD2) 
expression in the breast carcinoma tissues following exemestane (EXE) treatment, and further 
reported that 17βHSD2 expression was induced by both DHT and EXE in a dose dependent 
fashion in their in vitro studies [28]. These results indicated that aromatase, whose substrates 
include testosterone, may act as a negative regulator for in situ production of DHT in breast 
carcinoma tissue. Therefore, the study of alterations of these in situ androgen metabolisms 
following AIs treatment can provide very important information, toward a better understanding of 
the changes of the local endocrine environment associated with estrogen depletion. In particular, 
the comparison of the specimens between pre- and post-AIs treatment in neoadjuvant therapy may 
provide important information as to the changes in the intratumoral intracrine environment caused 
by AIs.  
 
1.4 Aromatase inhibitors and breast cancer 
  Estrogens play pivotal roles in influencing the ER positive breast cancer, as described above. 
Therefore, the beneficial effects of estrogen depletion on breast cancer have been widely reported 
[3]. Two primary strategies have been pursued to reduce the growth stimulatory effects of 
estrogens as follows: (1) interfering with the ability of estrogens to bind to its receptor 
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(antiestrogens), and (2) decreasing circulating levels of estrogens (estrogen deprivation or 
depletion). Currently available antiestrogens (e.g., tamoxifen, a selective estrogen-receptor 
modulator) exhibit both estrogen agonist and estrogen antagonist effects depending on the tissue 
type and the hormonal environment within which they are acting. These antiestrogens remain their 
estrogenic effects that may lead to some significant adverse consequences, such as 
thromboembolic disease and secondary uterine and other cancers. The estrogen deprivation, by 
surgical or systemic methods, offers another mechanism to inhibit the hormonal dependent breast 
cancer cell growth. Although the surgical approaches (such as ovariectomy, adrenalectomy, and 
hypophysectomy) to estrogen ablation are effective, but, they lack specificity and show 
significantly adverse side effects [25]. The elucidation of intratumoral estrogen production by the 
group of Miller [12] and the consequential exploration of the estrogen biosynthetic pathway by 
many investigators [3, 11, 13-16] have identified another potential target, AIs, as described above. 
The conversion of androgens (testosterone and androstenedione) to estrogens (E2 and E1) by 
aromatase is a unique reaction step in estrogen biosynthesis (Figure 1).   
 The aim of AIs neoadjuvant treatment is to decrease tumor volume through the delivery of 
drugs before surgery, thereby facilitating a more complete surgical removal of the tumor and 
improved patient survival. The AIs offer the new treatment options for the breast cancer patients, 
and can be categorized based on their chemical structure as follows: (1) Type I, or steroidal, AIs 
which are derivatives of androstenedione and bind irreversibly to aromatase, (2) Type II, or 
nonsteroidal, AIs which are competitive inhibitors that bind to the heme moiety of the aromatase 
CYP complex [25]. The first generation AI, aminoglutethimide, is nonselective AI because it 
inhibits many other enzymes necessary for the steroidal biosynthesis, including those required for 
cortisol production. It is not therefore an ideal treatment option. The second-generation AI, 
formestane, is selective for aromatase but it requires bimonthly intramuscular injection and is not 
effective as compared with tamoxifen. The third-generation AIs including both steroidal AI; EXE, 
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and non-steroidal AIs; anastrozole (ANA) and letrozole (LET), are potent AIs that are 
administered orally once daily [25]. 
 It is true that these new generations of AIs have shown more efficacy and effectiveness than 
ever before. However, clinical resistance to these endocrine therapies still occurs, which has 
resulted in serious clinical adverse problems in the management of these patients above. The 
mechanisms of this endocrine resistance have been examined by many investigators from the 
standpoints of either de novo or intrinsic and acquired resistances. Mechanisms of intrinsic or de 
novo resistance were evident at an initial exposure to endocrine therapy even in some ER abundant 
tumor cases [4]. The exact mechanisms for this type of resistance are still unknown at this juncture. 
Acquired resistance usually develops during the course of endocrine therapy to the patients who 
initially respond to the AIs treatment. This mode of resistance has been, in general, explained by a 
possible adaptation of carcinoma cells to acquire the potential to proliferate despite the inhibition 
or suppression of aromatization or in situ depletion of estrogens, i.e., de novo acquirement of novel 
signaling mechanisms to develop a state of estrogen hypersensitivity in breast carcinoma cells, 
which subsequently circumvent the clinical effects of AIs [4, 22]. 
  Multiple clinical trials have been recently designed in order to examine these resistance 
mechanisms of AIs [4, 20-24]. A number of putative theories have been proposed to explain the 
development of this resistance to AIs during the treatment. However, an adaptation of hormone-
dependent breast carcinoma cells to estrogen withdrawal or depletion, and the development of 
estrogen hypersensitivity are considered to represent the common biological features of AIs 
resistance [4, 29-33].  It is also important to note that enzymes other than aromatase are indeed 
involved in intratumoral estrogen synthesis in human breast cancer tissues, as described above. 
   Therefore, in this study, I hypothesized that alternative sources of intratumoral estrogen 
production may be one of the causes of clinical resistance of the ER positive breast cancer patients 
to the neoadjuvant endocrine therapy or to AIs treatment.   
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 I first evaluated the changes of the enzymes involved in intratumoral estrogen production 
including STS, 17βHSD1 and EST in breast carcinoma tissues before and after the neoadjuvant 
EXE treatment of the JFMC34-0601 trial study using the immunohistochemistry (IHC) in order to 
study the alteration of these enzymes after AIs treatment in 49 cases of that study. I then correlated 
the findings with the therapeutic responses of individual patients, including clinical and 
pathological responses, and alterations of Ki67 before and after the therapy of individual patients, 
as well as with those of ER, progesterone receptor (PgR), and human epidermal growth factor 
receptor type 2 (Her2) in breast carcinoma, in order to examine the correlation of these findings 
with AIs response or resistance in the individual patients.  
 It is very important to study not only the alteration of intratumoral estrogenic enzymes, but 
also the alteration of androgenic enzymes for which interplay pivotal roles in the breast carcinoma 
cells following AIs treatment, as mentioned above, in order to study the alteration of intratumoral 
hormonal microenvironment in breast cancer tissue following AIs treatment. Therefore, I also 
evaluated the alterations of androgenic enzymes, including 17βHSD5, 5αRed1 and 5αRed2, as 
well as AR expression in breast cancer tissues, before and after the neoadjuvant AIs treatment 
using IHC, and then correlated the findings obtained, with the alteration of Ki67 in breast cancer 
tissues, as well as those of ER, PgR, and Her2 of individual patients, before and after the therapy, 
in order to further investigate these changes of intratumoral androgen producing pathways that 
may be correlated with the estrogen producing pathways.  In particular, I evaluated the clinical and 
biological significance of intratumoral androgenic enzymes, especially 5αRed2, in association 
with the decreased Ki67 from estrogen depletion caused by AIs therapy in order to study the 
alteration of these enzymes in the AIs response group.  
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Chapter 2 
Materials and Methods 
2.1 Study of changes of estrogenic enzymes in breast cancer tissue after EXE 
treatment 
2.1.1 Patients 
From March, 2006 to January, 2008, a neoadjuvant AIs study of JFMC34-0601 [34] of the 
Japanese Foundation for Multidisciplinary Treatment of Cancer was conducted in Japan. One 
hundred and sixteen Japanese postmenopausal patients (age 55-75 years old), in whom the 
operable primary breast cancers had been histologically diagnosed as primary invasive ductal 
carcinoma, TNM stage II-IIIA, were enrolled into the study. According to the protocol of that 
study, the menopausal status was defined by natural menopause: at least one year since the last 
menstrual period, with the serum level of Follicle-stimulating hormone (FSH), and plasma E2 
within the postmenopausal range (FSH ≥ 30 IU/L, E2 < 10 pmol/L). None had received prior 
treatment with hormonal agents, chemotherapy or endocrine therapy for breast cancer, nor was 
taking any medications, including hormonal preparations, at the time of that study. None had the 
past history of breast cancer. All the patients gave informed consents to that study, which had been 
approved by the corresponding local ethics committees or institutional review boards.  
The JFMC34-0601 trial study was a multicenter phase II study by the Japanese Foundation 
for Multidisciplinary Treatment of Cancer, performed from March, 2006 to January, 2008. The 
study was conducted to evaluate the possible efficacy and safety of EXE treatment for 24 weeks 
administration in Japanese breast cancer patients. One hundred and sixteen Japanese 
postmenopausal patients were enrolled and all of them had been diagnosed as primary operable 
invasive ductal carcinoma of the breast. The primary clinical endpoints were the objective 
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response rates and the safety after 24 weeks of the EXE treatment. Results of that trial study 
demonstrated that 24-week EXE treatment was more effective than 16-week administration [34]. 
According to the protocol of that study, all 116 patients initially received EXE as an oral 
dose 25 mg daily for 16 weeks, and then subsequently an additional 8 weeks of treatment was 
provided after clinical evaluation. Tumor size was serially monitored by calipers and breast 
ultrasound before and after treatments, at 16 weeks and at 24 weeks after receiving the 
neoadjuvant therapy. At week 16, the clinical response was assessed, and if the patients were 
evaluated as clinical responders (complete response or partial response or stable disease); 8 weeks 
of the same treatment was subsequently added, until the total treatment period of 24 weeks was 
reached. However, if the patients were classified as clinical non-responders (progressive disease), 
these patients either underwent surgery or received other modes of treatment. All the patients with 
an exception of ten patients (6 discontinued the treatment because of adverse effects, and 4 were 
classified as non-responders) continuously received the therapy, until they reached the total period 
of 24 weeks of treatment. At 24 weeks of the treatment, clinical response was re-evaluated and all 
the patients underwent surgery. The pre- and post-treatment specimens of 49 patients among 116 
patients were available for my study of pathological response and their immunohistochemical 
evaluation. All paraffin blocks of the rest of the study (67 patients) were unavailable due to the 
restrictions of institutional review board in individual institutions which for some reasons 
prohibited the translational research using the specimens of those patients. The specimens 
available for the examination in my study were therefore pre-treatment core needle biopsies and 
post-treatment surgical specimens, which were obtained after the surgery at week 16 or 24. ER, 
PgR and Her2 status were performed by individual institutions, using standard procedures, and 
then the data were retrieved for centrally reviewed and analyzed.  
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2.1.2 Clinical response 
  Clinical response was based on the changes in tumor volume taken at 16 weeks and/or 24 
weeks after the neoadjuvant therapy. Clinical response was defined as complete response (CR), 
partial response (PR), stable disease (SD), or progressive disease (PD) according to the Response 
Evaluation Criteria in Solid Tumors [35]. 
 
2.1.3 Pathological response 
  Tissue sections of the same tumors from pre-treatment core needle biopsies and final 
surgical specimens were obtained and assessed for changes in cellularity and degree of fibrosis by 
microscopic examination of their hematoxylin-eosin stained slides. Pathological response was 
categorized, using the modified criteria reported by the group of Miller [36], and assessed as 
follows: complete when there was no evidence of malignant cells at the original tumor site; partial 
response when histological decrement in cellularity and/or increment in fibrosis were detected; or 
no change/non-response.  
 
2.2 Study of changes of androgenic enzymes in breast cancer tissue after AIs 
treatment 
2.2.1 Patients  
The specimens available for my study were pre- and post-treatment samples that were 
obtained from Celecoxib Anti-aromatase Neoadjuvant trial (CAAN trial). That study was a 
neoadjuvant AIs clinical trial study that was conducted at The University of Hong Kong and 
Queen Mary Hospital, Hong Kong, from November, 2001 to April, 2004. The study design was 
previously reported [37]. In brief, it was conducted to investigate the efficacy and safety of 
neoadjuvant therapy combining AIs with cyclooxygenase 2 (COX-2) inhibitor. Eighty-two 
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patients enrolled in that neoadjuvant study were postmenopausal women with histological proof of 
invasive ductal breast carcinoma and positive ER/PgR status determined by IHC analysis that was 
evaluated in Department of Pathology, Queen Mary Hospital, The University of Hong Kong [37]. 
According to the protocol of that study, the inclusion criteria were as follows: an Eastern 
Cooperative Oncology Group (ECOG) performance status ≤ 3 or a Karnofsky performance score ≥ 
70, the ability of the patient to provide written consent and follow instructions well, clinical size of 
tumor ≥ 3 cm. The exclusion criteria included negative estrogen receptor status, known sensitivity 
to anti-aromatase drugs or celecoxib, major cardiac or left ventricular ejection fraction < 50%, 
coronary artery disease, active liver disease, renal impairment, and prior history of other 
malignancy within 5 years of study entry except for basal cell carcinoma of the skin or carcinoma 
in situ of the uterine cervix. Informed consents had been obtained from all the patients prior to 
their enrollment into that clinical trial study, which had been approved by the local ethics 
committee. 
According to the protocol of CAAN trial, the patients were randomly assigned to receive 
EXE 25 mg daily and celecoxib 400 mg twice daily (group A, n = 30), EXE 25 mg daily (group B, 
n = 24) and LET 2.5 mg daily (group C, n = 28), respectively. Each patient was treated for 3 
months and the subsequent surgery was performed within 7 days after the last cycle of treatment. 
As reported previously, there were no significant differences in term of clinical and pathological 
responses among these three different treatment groups [37]. Therefore, the responses toward AIs 
therapy were by no means influenced by the concurrent use of celecoxib.  
           The pre- and post-treatment specimens of 29 patients among those patients were available 
for my study of pathological response and IHC evaluation, as described below. According to the 
protocol of CAAN trial, these 29 patients were randomly assigned to receive the treatment as 
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follows (group A, n = 10; group B, n = 8; group C, n = 11). Their mean age was 74.6 years (range, 
51-93 years). 
 
2.3 Immunohistochemistry  
  All immunohistological studies were performed on both pre-treatment core needle biopsies 
and final surgical specimens. One 4-µm section of each submitted paraffin block of pre- and post-
treatment specimens was stained with hematoxylin-eosin to verify the presence of an adequate 
number of invasive breast carcinoma cells and the quality of fixation in order to explore the 
suitability for further IHC analysis. In brief, serial tissue sections (4-µm) were prepared from 
representative tissue blocks and IHC was performed to immunolocalize ER, PgR, Her2, Ki67, STS, 
17βHSD1, EST as well as AR, 17βHSD5, 5αRed1, and 5αRed2, as described previously [20, 27, 
38, 39]. A Histofine Kit (Nichirei, Tokyo, Japan), employing the streptavidin-biotin amplification 
method, was used for IHC staining. The lists of primary antibodies employed in my present study, 
the working dilutions of individual antibodies, and the details of antigen retrieval methods were all 
summarized in Table 1. The antigen-antibody complex was visualized with 3, 3’-
diaminobenzidine (DAB) solution (1 mM DAB, 50 mM Tris-HCl buffer (pH 7.6), and 0.006% 
hydrogen peroxide (H2O2), and counterstained with hematoxylin. Tissue sections of full-term 
placenta were used as positive controls for STS, 17βHSD1, and EST. In addition, tissue sections of 
normal human liver were used as positive controls for 5αRed1 and 5αRed2 as well as those of 
testis and prostate gland for 17βHSD5 and AR, respectively. 
STS, 17βHSD1 and EST immunoreactivity was evaluated using the following semi-
quantitative method: score 2, >50% positive cells; 1, 1-50% positive cells; and 0, no 
immunoreactivity, as previously described by the group of Sasano [20] (Figure2).  
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17βHSD5, 5αRed1, and 5αRed2 immunoreactivity was all evaluated using a semi-
quantitative method as follows: score 2, >50% positive cells; score 1, 1-50% positive cells; and 
score 0, no immunoreactivity, as previously described by the group of Sasano [40] (Figure 3). 
Evaluation of Ki67 was performed by counting 1,000 carcinoma cells or more from each case and 
the percentage of immunoreactivity was subsequently determined as a labeling index (LI) [38]. 
In addition, the Ki67 LI was then subclassified, based upon the criteria reported by the 
group of Miller [36], into three different groups according to the percentage of Ki67 alterations 
after treatment as follows: Group1; “the increased group”, in which the Ki67 LI increased after the 
therapy. Group2; “the no change group”, in which the Ki67 LI was unchanged or reduced to less 
than 40% of the pre-treatment level. Group3; “the decreased group”, in which the Ki67 LI was 
reduced to more than 40% of the pre-treatment level.    
ER, PgR and AR immunoreactivity was scored by assigning proportion and intensity 
scores, based upon Allred’s procedure [41]. In brief, a proportion score represented the estimated 
proportion of immunopositive tumor cells as follows: 0 (none), 1 (<1/100), 2 (1/100 to 1/10), 3 
(1/10 to 1/3), 4 (1/3 to 2/3), and 5 (>2/3). An intensity score represented the average 
immunointensity of the positive cells as follows: 0 (none), 1 (weak), 2 (intermediate), and 3 
(strong). Any discernible nuclear immunoreactivity in individual breast carcinoma cells was 
counted toward both proportion and intensity scores. The proportion and intensity scores were then 
added to obtain a total score that could range from 0 to 8. The membrane staining pattern was 
evaluated in Her2 IHC and scored on a scale of 0 to 3 [42].  
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2.4 Statistical analysis 
The software SPSS 15.0 (Inc, Chicago, IL, USA) was used in my present study. Several 
statistical tests were used for the testing as follows: the Mann-Whitney U-test was used to compare 
the pre-treatment IHC scores of all biological markers according to the clinical and pathological 
responses to EXE treatment in 49 obtained patients from JFMC34-0601 study. The Wilcoxon 
matched-pairs signed-ranks test was used in order to determine the mean differences between pre- 
and post- treatment IHC scores of each individual biological marker in relation to both the clinical 
and pathological responses’ status and the alterations of Ki67 LI in 49 patients from JFMC34-0601 
study as well as those in 29 patients from CAAN study. The correlation among intratumoral 
estrogenic enzymes (STS, 17βHSD1 and EST) and intratumoral androgenic enzymes (17βHSD5, 
5αRed1 and 5αRed 2) was also analyzed using Spearman’s rank nonparametric correlation. The 
Kruskal-Wallis test was used to compare the pre-treatment IHC scores of all biological markers in 
29 patients from CAAN study, according to three groups of AIs treatment in individual patients. 
Logistic regression analysis was performed to determine whether the changes in androgenic 
enzymes, especially 5αRed2, predicted for decreased Ki67 LI/response group or not. The 
statistical significance was considered as the p value < 0.05.  
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Chapter 3 
Results 
3.1 Results of the study of the changes of estrogenic enzymes in breast cancer 
tissue after EXE treatment  
Forty-nine breast carcinoma specimens from JFMC34-0601 trial study examined before the 
EXE treatment demonstrated the following features after the central review of the specimens: ER+ 
(100%), PgR+ (85.7%) and Her2+ (77.6%).  
 
3.1.1 Clinical and pathological responses 
  The relevant clinical findings of 49 patients in JFMC34-0601 trial study for understanding 
were summarized in Table 2.  
All forty-nine patients received 16 weeks of EXE treatment, but 2 patients were evaluated 
as PD, and the subsequent surgery was advocated at 16 weeks of treatment. Only 47 patients were 
continuously administrated for the EXE treatment until 24 weeks. Clinical response was re-
evaluated, and clinical responders were classified as PR in 27 cases or 55.1% while clinical non-
responders included 19 cases of SD (38.8%), and 3 cases of PD (6.1%) including those previously 
evaluated as PD (2 patients). Pathological responders and non-responders corresponded to 22 
cases (44.9%) and 27 cases (55.1%), respectively. The correlation between clinical and 
pathological responses was demonstrated in Table 3 but the statistical significance could not be 
detected (p = 0.5809; Fisher exact test). 
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3.1.2 Pre-treatment evaluation of biological markers according to the responses 
to EXE treatment 
The means of individual biological markers, which were subjected to various responses to 
the EXE treatment, were demonstrated in Table 4.  
No statistical significance was detected in all the markers examined between clinical and 
pathological response and non-response groups, except for Her2 scoring which was higher in 
pathological non-response group than that of response group (Table 4).  
 
3.1.3 Associations between alterations of biological markers during the therapy 
and responses to EXE treatment in individual patients 
Alterations of immunohistochemical biomarkers examined in breast tumor tissues before 
and after EXE neoadjuvant treatment according to clinical and pathological responses were 
summarized in Table 5 and Table 6.  
In clinical response group, the significant decrement of Ki67 LI (p < 0.0001),  
ER (p = 0.0098) and PgR expression (p < 0.0001) was detected. In addition, the statistically 
significant increment was demonstrated in STS (p = 0.0084) and 17βHSD1 (p = 0.0015). EST also 
demonstrated some degrees of increment but that increment did not reach statistical significance  
(p = 0.375) (Figure 4). Among clinical non-responders, STS, 17βHSD1 and EST were all 
significantly increased (p = 0.0078, p = 0.0010 and p = 0.0313, respectively). In addition, PgR and 
Ki67 LI demonstrated significant decrement (p = 0.0034 and p = 0.0003, respectively) but ER and 
Her2 status did not demonstrate any significant differences between before and after the therapy 
(Table 5).  
In pathological response group, the significant decrement of IHC scores were demonstrated 
in ER (p = 0.0186), PgR (p < 0.0001) and Ki67 LI (p < 0.0001).  Among the enzymes examined, 
only 17βHSD1 demonstrated statistically significant increment (p = 0.0068) (Table 6).  In contrast, 
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the intratumoral enzymes in pathological non-responders, STS, 17βHSD1 and EST were 
associated with statistically significant increment (p = 0.0002, p = 0.0001 and p = 0.0156, 
respectively). In addition, the significant decrement was also detected in PgR (p = 0.0004) and 
Ki67 LI (p = 0.0003) following the therapy in this non- responder group (Table 6). 
 
3.1.4 Alterations of intratumoral enzymes and biological markers according to 
the changes of Ki67 labeling index 
Differences of the individual enzymes between pre- and post-treatment were evaluated 
according to these categories of Ki67 LI, as described above. Immunoreactivities of STS, 
17βHSD1, EST, ER, PgR and Her2 in pre-treatment specimens were not significantly different 
among these three different groups of Ki67 LI changes (Nonparametric ANOVAs; Data not 
shown).   
In group 1 (the increased group) in which the Ki67 LI was associated with increment 
following the therapy, no statistically significant differences of intratumoral enzymes and 
biomarkers was detected in the specimens between before and after the treatment. In group 3 (the 
decreased group) in which the Ki67 LI was reduced to more than 40% of the pre-treatment level, 
the significant increment of STS and 17βHSD1 was demonstrated (p = 0.0008 and p = 0.0003, 
respectively). In addition, ER and PgR scorings following the therapy demonstrated significant 
decrement compared to pre-treatment (p = 0.0013 and p < 0.0001, respectively) in group 3 patients. 
In group 2 (the no change group) in which the Ki67 LI was unchanged or reduced to less than 40% 
of the pre-treatment level, only 17βHSD1 was associated with statistically significant increment  
(p = 0.0313). In addition, among the enzymes examined and among the other biomarkers 
examined, only PgR status was significantly decreased following the therapy (p = 0.0117) in group 
2 patients. EST and Her2 scorings were not different among these three different groups of Ki67 
LI alteration (Table 7). 
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3.1.5 Correlation among STS, 17βHSD1 and EST immunoreactivity before and 
after EXE treatment 
Results were summarized in Table 8. The status of three enzymes examined in this study 
was significantly correlated among each other in tissue specimens before the therapy.  However, in 
tumor tissues following the therapy, only the status of STS and 17βHSD1 was significantly 
correlated each other. 
 
3.2 Results of the study of changes of androgenic enzymes in breast cancer 
tissue after AIs treatment 
Biopsies from 29 patients who had been treated with EXE and celecoxib (group A, n = 10), 
EXE (group B, n = 8), or LET (group C, n = 11), were available for evaluation of pathological 
response assessment and IHC study. Pathological responders and non-responders were 7 (24.1%) 
and 22 cases (75.9%), respectively. 
 
3.2.1 Immunohistochemistry 
The medians of pre-treatment individual biological markers were compared but displayed 
no statistical significance (Nonparametric ANOVAs; Data not shown).  I then analyzed the 
changes of IHC scores of all biological markers after the treatment.  The statistically significant 
reduction in PgR expression and Ki67 LI was detected (p = 0.0017 and p = 0.0439, respectively), 
as previously reported in LET [36], ANA [43], and EXE [39] neoadjuvant treatment but the 
expression levels of ER and AR were increased (p = 0.015 and p = 0.0127, respectively). On the 
other hand, the intratumoral androgenic enzymes demonstrated some degrees of increment but this  
increment detected did not reach statistical significance (Table 9). 
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3.2.2 An association of alterations of intratumoral androgenic enzymes and 
Ki67 LI 
Differences of the individual enzymes and other biological markers between pre- and post-
treatment were evaluated according to these categories of Ki67 LI described above. 
Immunoreactivities of ER, PgR, Her2, AR, 17βHSD5, 5αRed1 and 5αRed2 in pre-treatment 
specimens were not significantly different among these three different groups of Ki67 LI changes 
(Nonparametric ANOVAs; Data not shown). In group 1 (the increased group) in which the Ki67 
LI was associated with increment after therapy and group 2 (the no change group) in which the 
Ki67 LI was unchanged or reduced to less than 40% of the pre-treatment level, no statistically 
significant differences were detected in any of intratumoral enzymes and biomarkers examined 
between the specimens before and after the treatment. In group 3 (the decreased group) in which 
the Ki67 LI was reduced to more than 40% of the pre-treatment level, the significant increment of 
5αRed2 and AR and decrement of PgR expression were demonstrated (p = 0.025, p = 0.039 and  
p = 0.005, respectively), whereas the status of other biological markers did not show any 
statistically significance (Table 10) (Figure 5). 
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3.2.3 Correlation among intratumoral androgenic enzymes before and after AIs 
treatment 
I then examined the correlation between IHC scores of intratumoral enzymes in tumors 
before and after the treatment according to the categories of Ki67 LI. In pre-treatment group of 
the patients, androgenic enzymes including 17βHSD5, 5αRed1, and 5αRed2, were significantly 
correlated with each other (Table 11). Those correlations were, however, changed following AIs 
treatment. In group 1 (the increased group) whose Ki67 LI increased after the therapy, 17βHSD5 
was still correlated with 5αRed2 (p = 0.009) as well as 5αRed1 with 5αRed2 (p = 0.001) but loss 
of correlation between 17βHSD5 and 5αRed1 was detected (p = 0.067). In group 2 (the no 
change group) whose Ki67 LI unchanged or decreased with less than 40% of the pre-treatment 
level, only the correlation between 5αRed1 and 5αRed2 remained significant. Any correlation of 
these enzymes was not detected at all in group 3 (the decreased group) whose Ki67 LI decreased 
with more than 40 % of the pre-treatment level (Table 11).  
 
3.2.4 The relative importance of androgenic enzymes on Ki67 LI decrement  
           I further examined the effects of alterations of androgenic enzymes with relation to Ki67 
LI in order to determine whether these alterations, especially those of 5αRed2, were correlated 
with the status of response or non-response groups determined by Ki67 LI changes or not. Post-
treatment IHC status of each androgenic enzyme was further subclassified into three different 
groups according to the level of their alterations after treatment as follows: Group1; increased 
group, the status of the enzymes in this group was associated with an increment compared to the 
pre-treatment level. Group2; no change group, the status of the enzymes was the same as that in 
the pre-treatment level. Group3; decreased group, the status of enzymes was decreased following 
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the therapy. I could not find any significance among these groups in the logistic regression 
analysis but I detected that among three studied enzymes, the increased 5αRed2 group 
demonstrated the highest Odds ratio of the Ki67 decrement (Odds ratio = 3.739 and p = 0.397) 
(Table 12). 
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Chapter 4 
 Discussion 
Results of my present study provided pivotal new insights into the significant changes of 
intratumoral enzymes involved in the sulfatase pathway under estrogen depletion by EXE 
administration, and highlighted the importance of the potential interplay between intratumoral 
sulfatase and aromatase pathways signaling in breast carcinoma cells. In addition, I also 
demonstrated an alteration of the androgen producing enzymes following the AIs treatment, 
especially a de novo increment of 5αRed2 and AR, which has never been reported at all in the past 
and is considered at least one of the mechanisms to account for the decreased breast carcinoma cell 
proliferation following the treatment through an increment of local production of androgens and 
their actions via AR. These putative mechanisms firstly revealed by my present study indicated 
that the breast tissues, even when they are transformed into carcinoma, can still adapt themselves 
to keep the intratumoral hormonal microenvironment “estrogens and androgens” equilibrium in 
order to keep them survive in the estrogen deprived  state induced by AIs.  
Several clinical studies have been reported using EXE as primary endocrine therapy in the 
operable breast cancer patients but the results of clinical and pathological responses to EXE 
actually varied markedly among those studies [39, 44-46]. That is to say, the status of using EXE 
as primary endocrine therapy is still in dispute. In addition, the alterations in tumor 
histopathological features following the AIs administration including the changes in cellularity, 
degree of fibrosis, and histological grading [23, 36] as well as the treatment related changes of cell 
proliferation, apoptosis, and hormone receptor expression have been reported but the clinical 
significance of these histopathological findings has not been necessarily established [39, 43-48].  
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In tumor specimens following AIs therapy, one of the histological features most frequently 
or significantly affected included the number of mitotic figures or  Ki67 positive carcinoma cells, 
which decreased in the great majority of cases [23, 47, 48], usually more pronounced than 
tamoxifen therapy [48]. In IMPACT study, the group of Dowsett evaluated the alterations of the 
number of Ki67 positive carcinoma cells using IHC in 10% formalin fixed and paraffin embedded 
tissue sections of both pre-treatment and after two weeks of neo-adjuvant ANA treatment [43]. 
Fifty-two out of 56 patients (93%) were associated with some degree of Ki67 LI reduction over the 
only 2-week period of therapy. Reported results of subsequent IMPACT studies further 
highlighted the clinical or therapeutic importance of evaluating the changes of Ki67 LI of the 
breast carcinoma cells before and after the treatment [47]. 
 In the first part of my study, I also demonstrated marked decrement in cell proliferation 
evaluated by the changes of Ki67 LI between before and after the therapy in all clinical and 
pathological response and non-response groups, which was also consistent with the results of 
previously reported studies [23, 39, 43, 47, 49, 50]. Therefore, an inhibition of aromatase activity 
and subsequent in situ decreased tissue estrogen availability were considered to affect the 
expression of molecules present in the downstream of ER signaling pathways related to cell 
proliferation regardless of response to the treatment [3, 23, 39, 43, 47, 49, 50]. 
Changes of the enzymes other than aromatase involved in intratumoral estrogen 
biosynthesis following AIs therapy have been considered or postulated pivotal in relation to the 
development of treatment resistance [3] but have remained virtually unknown. To the best of my 
knowledge, my present study was the first investigation that demonstrated a significant increment 
of STS and 17βHSD1 following aromatase inhibitor neoadjuvant therapy of ER positive 
postmenopausal breast carcinoma patients [51]. I hypothesized that this increment of STS and 
17βHSD1 detected in my study may be due to the compensatory response of breast carcinoma 
tissues to the estrogen depletion, which may also represent an attempt of breast carcinoma cells to 
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increase the intratumoral estrogen concentrations by using the estrogen producing or metabolizing 
pathways other than aromatase.  In particular, the significant increment of STS and 17βHSD1 
following EXE treatment was detected in the group associated with decreased Ki67 LI in my 
present study (Table 7).  This increment of the enzymes above was not detected at all in the group 
associated with increased Ki67 LI, i.e., those associated with an absence of suppression of tumor 
cell proliferation.  However, it awaits further investigations to study in more details such as the 
intratumoral regulation of STS, 17βHSD1, and/or other enzymes under the influence of estrogen 
depletion state in order to substantiate this interesting hypothesis. 
 The simultaneous increment in STS and EST expression detected in my present study 
may be due to an intratumoral metabolism and synthesis of estrogens [51]. Both of these 
enzymes play pivotal roles in the intratumoral estrogen production in the hormone dependent 
breast carcinoma. STS hydrolyzes estrone sulfate (E1S) to E1, while EST sulfonates estrogens to 
inactive E1S [21]. The combined action of STS and EST could maintain the equilibrium 
between sulfated (inactive) and unconjugated (active) estrogens. Therefore, an increment of STS 
levels in breast carcinoma cells may result in increased intratumoral estrogen production, but 
EST expression may also increase as one of the counterbalance effects or responses to an 
increment of intracellular estrogen to maintain the equilibrium of intracellular estrogen 
production. However, it awaits further investigations to study the mechanisms of this 
simultaneous increment of both enzymes. 
  Among these estrogenic enzymes examined, in particular, 17βHSD1 was an only 
intratumoral enzyme whose expression increased regardless of clinical response, pathological 
response or Ki67 changes of the patients. The group of Sasano reported that the status of 
17βHSD1 immunoreactivity in carcinoma cells was significantly correlated with that of ER and 
PgR, suggesting that E2, synthesized by 17βHSD1 in carcinoma cells, acts on these cells locally 
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in breast carcinomas [40]. In addition, the reductive 17β-hydroxysteroid dehydrogenases are the 
last step in estrogen activation and thus play pivotal roles in biological behavior of ER positive 
breast carcinoma cells [52]. The group of Sasano [21] also reported that the status of 
intratumoral aromatase, 17βHSD1, EST and STS in human breast cancer tissues varied 
markedly among different cases and, especially, no significant correlation was detected between 
intratumoral aromatase and 17βHSD1.  Therefore, an inhibition of 17βHSD1 may be considered 
to confer the clinical or therapeutic benefits upon the patients in whom over-expression of 
intratumoral 17βHSD1 but not of aromatase was present in breast cancer tissues. The analysis of 
STS and 17βHSD1 using IHC is considered important because these inhibitors may not work 
unless these enzymes or targets are not present or overexpressed in breast carcinoma cells.  
Therefore, an analysis of these enzymes as potential surrogate markers of treatment may be 
required for the successful clinical outcome of treatment when some specific inhibitors against 
these enzymes will be clinically available.  
In the first part of my study, I have investigated the changes of STS, 17βHSD1, and EST 
and of other predictive factors using the pre-treatment tumor biopsies and post-treatment surgical 
specimens in the EXE treatment of ER positive primary breast cancer of postmenopausal patients. 
More than 95% of pre-treatment tumors demonstrated expression levels of ERα were 5 or greater 
by Allred’ score but the clinical and pathological responses to EXE varied among them.  Several 
clinical trials on EXE as primary endocrine treatment for hormone receptor positive operable 
breast cancer have been reported [39, 45, 46]. 
Results of my present study demonstrated that PgR expression was downregulated in a 
significant proportion of patients, which was similar to the results of several previously reported 
trials [39, 45, 46]. By contrast, the group of Takei reported that no correlation was detected 
between PgR and Her2 expression or in clinical or pathological response by PgR or Her2 status 
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[44]. The group of Ellis reported that the aromatase inhibitor, LET, but not tamoxifen, was 
effective in Her2 positive tumors as the neoadjuvant therapy in ER-positive breast cancer [50].  In 
addition, the significantly decrement of proliferative labeling index, Ki67, was demonstrated and 
correlated with relapse-free survival as demonstrated in a previous study [47]. 
To the best of my knowledge, the first part of my present study did represent the first 
reported study demonstrating the significant increment of STS and 17βHSD1 following AIs 
neoadjuvant therapy of ER positive breast carcinoma patients. Results clearly demonstrated an 
inhibition of aromatase activity and subsequently estrogen production by EXE administration 
influenced the expression status of molecules present at the downstream of ER signaling pathways 
regardless of the response. Based upon those above, I hypothesized that an increment of STS and 
17βHSD1 detected in my present study is considered to be due to the compensatory response of 
breast cancer tissues to estrogen depletion and is considered as a result of attempt of breast 
carcinoma to increase intratumoral estrogen concentrations using the pathways other than 
aromatase.  Despite the absence of reported study confirming the hypothesis which I proposed 
based upon my present study of the AIs treatment before, several cell culture and animal model 
studies indicated the adaptability of breast carcinoma cells to estrogen deprivation, for example, an 
up-regulation of co-activator mRNA and HER-2/neu during treatment with AIs (ANA and LET) in 
the in vivo study using real-time RT-PCR and up-regulation of Her2 after LET treatment in MCF-
7Ca cell lines which demonstrating that breast tumor cells under stress of treatment can adapt and 
utilize alternate pathways [4, 29, 32, 33].  
In addition, the study of the group of Santen [31] which evaluated the transcriptional 
responses to E2 in (LTED) MCF-7 cells with a cDNA microarray containing 1901 known genes 
and ESTs using real time PCR revealed that seven genes and one EST were induced by E2 in 
LTED but not in wild type MCF-7 cells. The hypothesis proposed in my present study may be 
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consistent with the results of the studies above regarding the potential mechanisms of adaptation 
and resistance of breast carcinoma cells to estrogen withdrawal or depletion by AIs administration 
but it awaits further investigations for clarification.  Therefore, further studies in larger population 
as well as an analysis of a large panel of resistant cell lines using microarray; an unbiased genome-
wide examination of signaling pathways responsible for steroidal and non-steroid AIs-resistance, 
would be beneficial for better understanding the molecular mechanisms in breast cancer for such 
occurrence. 
In order to study the alteration of intratumoral hormonal microenvironment in breast cancer 
tissues following AIs treatment, it is important to study not only the alterations of intratumoral 
estrogenic enzymes, but also those of androgenic enzymes which play pivotal roles in the breast 
carcinoma cells following AIs treatment, as mentioned above. I originally demonstrated an 
increment of the intratumoral enzymes following AIs therapy in the compensatory direction 
toward increasing intratumoral estrogen production [51]. However, the alteration of androgen 
metabolizing enzymes as a result of the neoadjuvant hormonal breast cancer therapy had not been 
examined at all. Therefore, in the second part of my study, I paid attention on the study of 
androgenic enzymes in the ER positive breast cancer tissues that may be alter after the AIs 
treatment.  
Numerous studies had been reported on the possible roles of androgen in human breast 
cancer but it was also true that controversies exist as to clinical or biological significance of 
androgens especially in estrogen dependent breast cancer [5-10, 27, 28]. Sonne-Hansen and 
Lykkesfeldt [10] reported that the aromatase activity in the MCF-7 cells was sufficient for the cells 
to aromatize testosterone to estrogen. This aromatization was also reported to result in significant 
cell growth stimulation. They also reported that both the steroidal and non-steroidal AIs could 
completely abolish the growth-stimulatory effect of testosterone. However, the group of Macedo 
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[5] demonstrated that androgens, such as androstenedione and DHT, inhibited MCF-7 cell 
proliferation in a low-estrogen concentration. In addition, LET treatment inhibited the breast 
carcinoma cell proliferation by both inhibiting conversion of androgens to estrogen, thereby 
making androgens available to exert their anti-proliferative effect with up-regulation of AR 
expression. 
 The second part of my study demonstrated statistically significant AR increment after the 
AIs treatment which confirms the previous studies mentioned above, however, the group of 
Yamashita did not detect this alteration during the EXE treatment [39]. The group of Sasano 
reported that intratumoral DHT of human breast cancer tissues was mainly determined by 5αRed1 
and aromatase [53]. However, in my present study, I initially demonstrated the correlation between 
the effects of AIs treatment and the changes of androgenic enzymes expression. The significant 
correlation was detected between the decrement in Ki67 LI or biological response of AIs and the 
increment of 5αRed 2 following AIs administration in breast carcinoma patients. 
Locally produced estrogens play a major role in proliferation of estrogen dependent breast 
cancer and androgens are considered to predominantly exert anti-proliferative effects via AR [26]. 
Intratumoral estrogens can be produced from circulating androgens, especially those derived from 
the zona reticularis of adrenal cortex, catalyzed by the aromatase enzyme in which the neoadjuvant 
AIs treatment blocks this enzyme with immense potency and exquisite specificity [23]. Local 
androgen concentrations have been well known to be significantly increased in breast cancer 
following AIs treatment, as previously reported in various in vitro studies [5-7, 27, 54]. The group 
of Sasano recently demonstrated the increment of DHT concentration in breast carcinoma tissue 
following the EXE therapy as well as inhibitory effects of DHT on estradiol-mediated T-47D cells 
proliferation [28]. These findings all suggested that AIs not only suppress aromatase enzymes and 
cause estrogen depletion in consequence, but also provide additional effects through increasing 
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local DHT concentration which may result in decreased cell proliferation of tumor cells.  These 
findings were consistent with the results of my present study that the statistically significant 
increment in 5αRed2 enzymes was detected only in the group associated with the reduction of 
Ki67 LI with more than 40 % of the pretreatment level or group 3 (p = 0.025) (Table 10).  
Following AIs treatment, an accumulation of in situ androgens in breast cancer tissues may occur 
and the enzyme 5αRed2 can serve as an important regulator of local actions of androgens because 
this enzyme converts testosterone into the biologically more active and nonaromatizable DHT [6, 
11, 27]. However, further studies such as the analysis of much larger number of neoadjuvant 
treated patients are required for confirmation. 
The potent and direct inhibitory effects of DHT on human breast cancer growth were firstly 
demonstrated by the group of Poulin in 1988 [55]. Two isoforms of 5α-reductases have been 
known to exist, encoded by different genes: SRD5A1 (chromosome 5p15) and SRD5A2 
(chromosome 2p23) [56, 57]. The two types of 5α-reductases share 50% amino acid sequence 
identity and possess similar substrate specific but have different optimal pH and sensitivity to 
inhibitors [57]. 5αRed2 is the major form of the enzyme expressed in the human prostate [57] but 
rarely detected in human breast carcinoma [53]. Both groups of Wiebe [58] and Suzuki [27, 53] 
demonstrated the expression of 5αRed1 in several types of human breast carcinoma cell lines 
using semi-quantitative RT-PCR and in human breast carcinoma tissues using IHC and RT-PCR, 
respectively. In addition, significant increment of 5αRed1 and 5αRed2 genes expression of human 
breast carcinoma as compared to normal breast tissue has been illustrated in the semi-quantitative 
RT-PCR study [59].  However, the regulatory mechanisms of 5αRed2 in human breast carcinoma 
have remained largely unknown and it awaits further investigations for clarification. 
In the second part of my present study, I did not, however, detect the significant alterations 
in the enzymes involved in androgen metabolism in non-response groups (groups 1 and 2) (Table 
 39 
10). This finding suggests that androgen metabolism is not influenced by the AIs in these groups 
of patients with breast cancer or non-responders. The loss of correlation of intratumoral 
androgenic enzymes in breast carcinoma tissue; 17βHSD5, 5αRed1 and 5αRed2, after AIs 
treatment (Table 11) as well as the alterations of 5αRed1 and 5αRed2 enzymes (Table 9) were 
detected, but these changes did not reach statistically significance. This may be due to the 
relatively small size of the patients examined, especially the rather limited number of available 
specimens in the second part of my study. I have additionally found that there were trends to 
greater reduction of Ki67 LI tended to be associated with an increased 5αRed2 but this correlation 
did not reach statistical significance (Table 12). 
After menopause, most of the biologically active androgens (as well as estrogens) are 
synthesized in peripheral intracrine tissue, for example in the breast, from precursors of adrenal 
origin without release of active androgens in the extracellular space and the circulation [6, 11]. In 
addition, DHT concentrations were demonstrated to be significantly higher in breast cancer tissues 
than in plasma [60]. Both 17β-hydrosteroid dehydrogenases and 5α-reductases have been 
considered to act to increase DHT production by competing with aromatase for substrates in the 
hormone-dependent breast carcinoma [28, 53]. As mentioned above, 5αRed1 is the predominant 
form of 5α-reductases at least in human breast cancer [28, 53, 57] but my present study clearly 
demonstrated the importance of 5αRed2, which is normally rarely expressed in breast cancer, but 
increased in response group or those associated with more Ki67 decrement.  
I therefore hypothesized that this rather de novo 5αRed2 increment may be related to the 
effects of AIs other than depleting in situ estrogens, i.e., the potential increment of the endogenous 
androgens which may exert their antiproliferative effects via the AR, especially in a low-estrogen 
milieu, as demonstrated in the breast cancer cell lines study [5] and possibly to be an induction in 
apoptosis signaling pathways. Androgens, androstenedione and DHT, were reported to have a 
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proapoptotic effect by strongly reducing Bcl-2 expression in MCF-7 cells, and this androgenic 
inhibitory effect was mediated by the AR [29, 61]. 
     To the best of my knowledge, the second part of my study has been the first study 
which demonstrated the alteration in the androgen producing enzymes following the AIs treatment, 
especially a de novo increment of 5αRed2, that may be considered at least one of the mechanisms 
to account for the decreased breast carcinoma cell proliferation after AIs therapy through an 
increment of local concentrations of androgens. However, the regulatory mechanisms of 5αRed2 
in human breast carcinoma have remained largely unknown and it awaits further investigations for 
clarification. 
Further investigations, such as a more detailed analysis of breast cancer microenvironment 
including the status of both estrogenic and androgenic enzymes following AIs therapy, are 
required to understand the complete features of biological changes of breast cancer tissues 
following estrogen depletion.  However, an identification of possible markers predicting the AIs 
resistance before the therapy, including those in my present study, will certainly improve the 
clinical response of ER positive patients to AIs therapy.  
In conclusion, to the best of my knowledge, my present thesis represents the first studies 
that demonstrated a subsequently significant increment of the estrogenic enzymes, STS and 
17βHSD1, as well as the alterations in the androgenic enzymes, especially a de novo increment of 
5αRed2, following the AIs treatment of ER positive breast carcinoma patients. 
Results of my present study indicated that: (1) the increment of intratumoral estrogenic 
enzymes, 17βHSD1 and STS, may represent at least one of the mechanisms  for  the development 
of resistance to AIs treatment in hormonal-dependent breast carcinoma cells,  (2) the increment of 
intratumoral androgenic enzymes, 5αRed2, and androgen receptor may partly contribute to 
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inhibition of the breast carcinoma cell proliferation through increasing androgenic actions to 
carcinoma cells, and (3) the alteration of the androgenic enzymes, especially a de novo increment 
of 5αRed2 as well as AR, following the AIs treatment may be considered at least one of the 
mechanisms which account for the decreased breast carcinoma cells proliferation. However, the 
regulatory mechanisms of 5αRed2 in the human breast carcinoma have remained largely unknown 
and it awaits further investigations for clarification. In addition, my recent work supports the 
concepts of breast cancer adaptable ability that breast cancer cells are able to adapt themselves, 
and may produce an appropriate intratumoral microenvironment, in order to response to pressure 
exerted by the hormonal therapies.  
I firmly believe here that my recent findings will certainly contribute to the worldwide 
clinical use of neoadjuvant endocrine therapy in breast cancer patients, and contribute to the 
rational design to further study about the novel therapeutic strategies combining antihormonal and 
biological targeted therapies for effectively treating the hormone-dependent breast cancer patients, 
hopefully toward for their better life and well-being. 
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Tables        
 
Table 1 The list of antibodies employed for immunostaining in this study 
 
Biomarkers Dilution 
Pre-treatment methods for antigen 
retrieval Providers 
    
STS(KM1049) 0.37µg/ml none * 
ER undiluted heat in automated machine Roche diagnostic, Germany 
PgR undiluted heat in automated machine Roche diagnostic, Germany 
Her2 undiluted heat in automated machine Roche diagnostic, Germany 
Ki67 1:100          autoclave in citric buffer DAKO, Glastrup, Denmark 
17βHSD1 1:400          microwave in citric buffer Abnova, Taipei, Taiwan 
EST 1:200          microwave in citric buffer MBL, Nagoya, Japan 
AR                                   1:50    autoclave in citrate buffer Dako, Denmark 
17βHSD5     1:200 not required           Sigma 
5αRed1     1:2,000 not required              * 
5αRed2     1:1,000 not required              * 
    
 
STS steroid or estrogen sulfatase, 17βHSD117β-hydroxysteroid dehydrogenase type 1, 
 EST estrogen sulfotransferase, Ki67 Ki67 protein, ER estrogen receptor,  
PgR progesterone receptor, Her2 human epidermal growth factor receptor type 2, 
 AR androgen receptor, 17βHSD5 17β-hydroxysteroid dehydrogenase type 5,   
5αRed1 5α-reductase type 1, 5αRed2 5α-reductase type 2 
* STS was kindly provided by, Kyowa medix Co Ltd, Japan, 5αRed1 and 5αRed2 were kindly 
provided by Dr. D.W. Russell (University of Texas Southwestern Medical Center, Dallas, 
Texas)        
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Table 2 Baseline characteristics of the patients (n = 49)  
Patients evaluable for IHC   49 
Mean age; years(range)  65.6 (56-77)  
Tumor stage, n (%)   
T2  49 (100) 
Nodal status, n (%)   
N 0  39 (79.6) 
N 1  10 (20.4) 
No distant metastasis, M0, n (%)  49 (100) 
Clinical stage, n (%)   
Stage IIA  39 (79.6) 
Stage IIB  10 (20.4) 
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Table 3 Correlation between clinical and pathological responses (n = 49)  
 
Clinical response 
 
                 Pathological response  Total 
         Response Nonresponse   
    
Complete response              0            0       0 
Partial response            12          15     27 
Stable disease              8          11     19 
Progressive disease              2            1       3 
Total            22          27     49 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 56 
Table 4 Correlation between immunohistochemical scores of biological markers in 
breast tumor before treatment and pathological and clinical responses to exemestane  
Biological markers Pathological response   Clinical response    
  R NR P value† R NR P value†  
 
STS 1.545±0.5 1.259±0.6 0.1745 1.333±0.6 1.455±0.6 0.5409  
ER 7.273±1.3 7.370±1.6 0.3247 7.704±0.5 6.864±2.0 0.1214  
PgR 4.955±2.4 4.889±2.9 0.8561 5.444±2.3 4.273±3.0 0.2082  
Her2 0.8636±0.9 1.444±0.8 0.0197* 1.259±0.9 1.091±0.9 0.5294  
Ki 67 14.045±12.5 11.444±9.5 0.6509 11.815±11.8 13.591±9.7 0.4448  
17βHSD1 1.409±0.5 1.296±0.5 0.5581 1.333±0.6 1.364±0.5 0.9266  
EST 1.727±0.5 1.704±0.5 0.8929 1.815±0.4 1.591±0.5 0.1756  
        
 
Data showed by means ± SD 
†Mann-Whitney U test for the difference between R and NR, R = response, NR = non-response; 
see text for the details 
*p value <0.05 is considered significant 
STS steroid or estrogen sulfatase, ER estrogen receptor,  
PgR progesterone receptor, Her2 human epidermal growth factor receptor type 2, 
Ki67 Ki67 protein, 17βHSD117β-hydroxysteroid dehydrogenase type 1, 
 EST estrogen sulfotransferase 
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Table 5 Comparison of pre- and post-treatment immunohistological scores of 
biological markers among groups of different clinical responses to exemestane     
     
Biologicalmarkers Clinical response   Clinical nonresponse   
  
Mean 
difference [95% CI] P value† 
Mean 
difference [95% CI] P value† 
       
STS -0.4444 [-0.7206, -0.1683]  0.0084* -0.3636 [-0.5820,-0.1453]  0.0078* 
ER 0.5556 [0.1401, 0.9710]  0.0098* 0.3636 [-0.1014,0.8286] 0.1289 
PgR 3.333 [2.346, 4.321] <0.0001* 2.318 [0.8481,3.788]  0.0034* 
Her2 0.1481 [-0.1139, 0.4102] 0.3394 0.04545 [-0.1699,0.2609] 0.8125 
Ki 67 7.074 [3.453, 10.965] <0.0001* 6.909 [3.301,10.517]   0.0003* 
17βHSD1 -0.4815 [-0.7109, -0.2521]   0.0015* -0.5 [-0.7269,-0.2731]  0.0010* 
EST -0.7407 [-0.2264, 0.07822] 0.375 -0.2727 [-0.4749,-0.07058]  0.0313* 
       
       
 
       
Data showed mean difference for pre IHC value-post IHC value with 95% CI [lower, upper values]; 
see text for the details 
†Wilcoxon match-pairs signed-ranks test for the difference between groups 
*p value <0.05 is considered significant 
STS steroid or estrogen sulfatase, ER estrogen receptor,  
PgR progesterone receptor, Her2 human epidermal growth factor receptor type 2, 
Ki67 Ki67 protein, 17βHSD117β-hydroxysteroid dehydrogenase type 1, 
 EST estrogen sulfotransferase 
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Table 6 Comparisons of pre- and post-treatment immunohistological scores of 
biological markers among groups of different pathological responses to exemestane 
       
Biological 
markers Pathological response   Pathological nonresponse   
  
Mean 
difference [95% CI] P value† 
Mean 
difference [95% CI] P value† 
       
STS -0.2727 [-0.5526, 0.007132] 0.1055 -0.5185 [-0.7479, -0.2891]   0.0002* 
ER 0.6818 [0.1450, 1.219]  0.0186* 0.2963 [-0.04751, 0.6401] 0.1094 
PgR 2.909 [1.859, 3.959] <0.0001* 2.852 [1.536, 4.167]   0.0004* 
Her2 0.04545 [-0.1699, 0.2609] 0.8125 0.1481 [-0.1139, 0.4102] 0.3394 
Ki 67 7.636 [4.216, 11.056] <0.0001* 6.481 [2.758, 10.205]   0.0003* 
17βHSD1 -0.4545 [-0.7188, -0.903]   0.0068* -0.5185 [-0.7200, -0.3170]   0.0001* 
EST -0.04545 [-0.2118, 0.1209] 0.75 -0.2593 [-0.4360, -0.08256]   0.0156* 
       
 
Data showed mean difference for pre IHC value-post IHC value with 95% CI [lower, upper values]; 
see text for the details 
†Wilcoxon match-pairs signed-ranks test for the difference between groups 
*p value <0.05 is considered significant 
STS steroid or estrogen sulfatase, ER estrogen receptor,  
PgR progesterone receptor, Her2 human epidermal growth factor receptor type 2, 
Ki67 Ki67 protein, 17βHSD117β-hydroxysteroid dehydrogenase type 1, 
EST estrogen sulfotransferase 
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Table 7 Comparison of pre- and post-treatment immunohistological scores of 
biological markers in breast tumors according to the degrees of Ki67 changes 
before and after exemestane treatment 
Biological  
markers 
Increase No change Decrease 
Mean difference p value† Mean difference p value† Mean difference p value† 
  [95% CI]   [95% CI]   [95% CI]   
          
STS -0.3333 0.5000 -0.4000 0.1250 -0.4242 0.0008* 
  [-1.417, 0.7507]   [-0.7694, -0.3062]   [-0.6231, -0.2253]  
17βHSD1 -0.3333 0.5000 -0.6000 0.0313* -0.4848 0.0003* 
  [-0.8753, 0.2087]   [-0.9694, -0.2306]   [-0.6855, -0.2842]  
EST -0.5000 0.0756 -0.1000 >0.9999 -0.1212 0.1563 
  [-1.075, 0.07489]   [-0.3262, 0.1262]   [-0.2685, -0.02606]  
          
ER 0.1667 >0.9999 -0.1000 >0.9999 0.6970 0.0013* 
  [-0.8653, 1.199]   [-0.3262, 0.1262]   [0.2956, 1.098]  
PgR 2.667 0.2500 2.800 0.0117* 2.939 <0.0001* 
  [-1.298, 6.631]   [0.9286, 4.671]   [1.905, 3.973]  
Her2 0.000 >0.9999 0.2000 0.3750 0.09091 0.4648 
  [-0.6638, 0.6638]   [-0.2524, 0.6524]   [-0.1145, 0.2963]  
              
 
Degrees of Ki67 changes were determined by the changes of labeling index after EXE treatment, i.e., 
pre value -post value, and subclassified into three groups.  
Data showed mean difference for pre IHC value-post IHC value with 95%CI [lower, upper values]; 
see text for the details.  
† Wilcoxon match-pairs signed-ranks test for the difference between groups 
 * p value <0.05 is considered significant 
 STS estrogen sulfatase, 17βHSD1 17β-hydroxysteroid dehydrogenase type 1,  
EST estrogen sulfotransferase, Ki 67 Ki 67 protein, ER estrogen receptor,  
PgR progesterone receptor, Her2 human epidermal growth factor receptor type 2  
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Table 8   Correlation between intratumoral enzymes involved in estrogen 
production before and after treatment with exemestane  
  STS VS. EST STS VS. 17βHSD1 EST VS. 17βHSD1 
        
Before treatment r = 0.5402 r = 0.5374 r = 0.4156 
    p < 0.0001*  p < 0.0001*   p = 0.0030* 
     
After treatment       r = 0.2743 r = 0.5983 r = 0.3403 
  p = 0.0565   p < 0.0001*          p = 0.0167 
        
 
Data showed by r value and p value calculated by Spearman’s rank nonparametric 
correlation test 
*p value < 0.05 is considered significant correlation 
 
 
 
 
 
 
 
 61 
Table 9 The alteration of biological markers before and after the treatment with 
aromatase inhibitors therapy  
      
 Pre-treatment value 
Mean [SEM] 
Post-treatment value 
Mean [SEM] 
Mean difference 
[95% CI] 
p value 
 
Biological 
markers  
           
      
17βHSD5 1.138 [0.128] 1.207 [0.135] -0.06879 0.6221  
   [-0.3165, 0.1786]   
5αRed1 1.552 [0.106] 1.689 [0.087] -0.1379 0.3394  
   [-0.3811, 0.1052]   
5αRed2 1.552 [0.106] 1.655 [0.114] -0.1034 0.5771  
   [-0.3971, 0.1902]   
AR 6.103 [0.295] 6.862 [0.242] -0.7586 0.0127*  
   [-1.3210, -0.1959]   
ER 7.034 [0.202] 7.586 [0.105] -0.5517 0.015*  
   [-0.9780, -0.1255]   
PgR 6.965 [0.195] 5.862 [0.321] 1.103 0.0017*  
   [0.3967, 1.810]   
Her 2 1.758 [0.146] 1.586 [0.168] 0.1724 0.2958  
   [-0.1163, 0.4661]   
Ki 67 16.352 [1.902] 12.162 [1.754] 4.19 0.0439*  
   [0.1332, 8.246]   
           
      
 
Data showed by mean (standard error of measurement [SEM]) of the IHC score of the pre- and 
post-treatment values; mean difference (pre- and post-treatment values) with 95% confidence 
interval [lower and upper values];  p value calculated by Wilcoxon’s matched-pairs signed-rank 
test  
17βHSD5 17β-hydroxysteroid dehydrogenase type 5, 5αRed1 5α-reductase type 1,  
5αRed2 5α-reductase type 2, AR androgen receptor, ER estrogen receptor,  
PgR progesterone receptor, Her2 human epidermal growth factor receptor type 2,  
Ki67 Ki67 protein  
*p value < 0.05 is considered significant 
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Table 10 The changes in biological markers after the aromatase inhibitors treatment 
grouped by the changes of Ki67 labeling index  
  Ki 67 increased (n = 11) Ki 67 unchanged (n = 6) Ki 67 decreases (n = 12) 
Biological 
markers Mean difference p value Mean difference p value Mean difference p value 
  [95% CI]   [95% CI]   [95% CI]  
       
       
17βHSD5 0.0909 0.655 -0.1667 0.564 -0.1667 0.317 
  [-0.3798, 0.5616]   [-0.9568, 0.6234]   [-0.5335, 0.2002]  
5αRed1 0.0909 0.564 -0.1667 0.564 -0.3333 0.102 
  [-0.2714, 0.4532]   [-0.9568, 0.6234]   [-0.7472, 0.08051]  
5αRed2 0.2727 0.276 -0.1667 0.564 -0.4167 0.025* 
  [-0.3349, 0.8804]   [-0.9568, 0.6234]   [-0.7438, -0.08949]  
AR -0.8182 0.164 -0.3333 0.625 -0.9167 0.039* 
  [-1.935, 0.2986]   [-1.604, 0.9378]   [-1.8730, 0.0396]  
ER -0.6364 0.053 -1.000 0.197 -0.250 0.317 
  [-1.257, -0.01537]   [-2.878, 0.8776]   [-0.8003, 0.3003]  
PgR 0.000 1.000 1.000 0.098 2.167 0.005* 
  [-0.6008, 0.6008]   [-0.3277, 2.328]   [0.7633, 3.570]  
Her 2 0.000 1.000 0.3333 0.157 0.250 0.317 
  [-0.5203, 0.5203]   [-0.2087, 0.8753]   [-0.3003, 0.8003]  
              
 
Data showed by mean difference (pre- and post-treatment values) with 95 % confidence interval 
 [lower value, upper value]; p value calculated by Wilcoxon’s matched-paired signed-rank test;  
n, sample in each group  
* p value < 0.05 is considered significant 
 17βHSD5 17β-hydroxysteroid dehydrogenase type 5, 5αRed1 5α-reductase type 1  
5αRed2 5α-reductase type 2, AR androgen receptor, ER estrogen receptor, PgR progesterone receptor, 
 Her2 human epidermal growth factor receptor type 2, Ki 67 Ki 67 protein 
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Table 11 The correlation between biological markers involve in androgen production 
 before and after the aromatase inhibitors treatment grouped by the changes in  
 Ki67 labeling index 
    Post-treatment  
Biological 
markers Before treatment (n=29) Ki 67 increased (n=11) Ki 67 unchanged (n=6) Ki 67 decreases (n=12) 
  5αRed1 5αRed2 5αRed1 5αRed2 5αRed1 5αRed2 5αRed1 5αRed2 
               
17βHSD5 0.59 0.695 0.57 0.743 0.316 0.316 0.243 0.477 
  (0.001)* (0.00)* (0.067) (0.009)* (0.541) (0.541) (0.446) (0.117) 
 
5αRed1   0.87   0.859   1.000  0.522 
    (0.00)*   (0.001)*   (0.00)* (0.082) 
                  
 
Data demonstrated by the correlation coefficient with (p value) calculated by Spearman’s rank correlation 
* p value < 0.05 is considered significant  
n sample in each group 
17βHSD5 17β-hydroxysteroid dehydrogenase type 5,  
5αRed1 5α-reductase type 1, 5αRed2 5α-reductase type 2, Ki 67 Ki 67 protein 
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Table 12 Odds ratio of each androgenic enzyme related to the Ki67 labeling index 
alterations following the aromatase inhibitors treatment   
          
Biological marker 
Post-treatment IHC 
status Odds ratio [95% CI] p value   
          
17βHSD5 Increase 0.368 [0.028,4.746] 0.443   
 Unchange reference     
 Decrease 0.696 [0.045,10.766] 0.795   
      
5αRed1 Increase 1.644 [0.156,17.359] 0.679   
 Unchange reference     
  Decrease cannot be calculated 1.000   
      
5αRed2 Increase 3.739 [0.177,79.081] 0.397   
 Unchange reference     
 Decrease 0.000 [0.000,-] 0.999   
 
 
Data showed the odds ratio of the Ki67 response with [95% confident interval] and p value 
calculated by logistic regression analysis; post-treatment IHC status means the change in the IHC 
score after the treatment; the unchanged of IHC scores after treatment was used as reference for the 
comparison 
17βHSD5 17β-hydroxysteroid dehydrogenase type 5, 
 5αRed1 5α-reductase type 1, 5αRed2 5α-reductase type 2, Ki 67 Ki 67 protein  
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 Figures 
 
 
Legends of figures 
 Figure 1  Major pathways of estrogens and androgens synthesis in human breast cancer tissue. 
DHEAS, dehydroepiandrosterone sulfate; DHEA dehydroepiandrosterone; A, androstenedione;  
T, testosterone; E1, estrone; E1S, estrone sulfate; E2, estradiol; STS, steroid or estrogen sulfatase; 
EST, estrogen sulfotransferase; 17βHSD1, 17β-hydroxysteroid dehydrogenase type 1; 17βHSD2, 
17β-hydroxysteroid dehydrogenase type 2; 17βHSD5, 17β-hydroxysteroid dehydrogenase type 5; 
5αRed1, 5α-reductase type 1; 5αRed2, 5α-reductase type 2; AR, androgen receptor; ER, estrogen 
receptor 
 
Figure 2 Representative illustrations of immunohistochemistry: (A) 17βHSD1 and (B) STS in a 
case of invasive ductal carcinoma. Immunoreactivity of both enzymes was detected in the 
cytoplasm of human breast cancer cells. Original magnification x200 
 
Figure 3 Representative illustrations of immunohistochemistry: (A) 17βHSD5 and (B) 5αRed2 
in a case of invasive ductal carcinoma. Immunoreactivity of both enzymes was detected in the 
cytoplasm of human breast cancer cells. Original magnification x200  
 
Figure 4 Illustrate changes in IHC scores of STS, 17βHSD1, EST and Ki67 labeling index. 
STS and 17βHSD1 immunoreactivity demonstrated significant increment in all tumor subgroups 
irrespective of clinical or pathological assessment status, but not in EST. Ki67 labeling index 
illustrated marked reduction after the treatment. 
Figure 5 Demonstration of the mean value of the intratumoral androgenic enzymes before and 
after the AI treatment grouped by the Ki67 LI response. Error bar represents ±2 standard error of 
measurement (SEM). The significant difference between pre- and post- treatment value was 
displayed with * (P < 0.05). 
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Figure 1  Major pathways of estrogens and androgens synthesis in human breast cancer tissue. 
DHEAS, dehydroepiandrosterone sulfate; DHEA dehydroepiandrosterone; A, androstenedione; T, 
testosterone; E1, estrone; E1S, estrone sulfate; E2, estradiol; STS, steroid or estrogen sulfatase; 
EST, estrogen sulfotransferase; 17βHSD1, 17β-hydroxysteroid dehydrogenase type 1; 17βHSD2, 
17β-hydroxysteroid dehydrogenase type 2; 17βHSD5, 17β-hydroxysteroid dehydrogenase type 5; 
5αRed1, 5α-reductase type 1; 5αRed2, 5α-reductase type 2;  
AR, androgen receptor; ER, estrogen receptor 
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Figure 2 Representative illustrations of immunohistochemistry: (A) 17βHSD1 and (B) STS in a 
case of invasive ductal carcinoma. Immunoreactivity of both enzymes was detected in the 
cytoplasm of human breast cancer cells. Original magnification x200 
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Figure 3 Representative illustrations of immunohistochemistry: (A) 17βHSD5 and (B) 5αRed2 
in a case of invasive ductal carcinoma. Immunoreactivity of both enzymes was detected in the 
cytoplasm of human breast cancer cells. Original magnification x200    
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Figure 4 Illustrate changes in IHC scores of STS, 17βHSD1, EST and Ki67 labeling index 
STS and 17βHSD1 immunoreactivity demonstrated significant increment in all tumor subgroups 
irrespective of clinical or pathological assessment status, but not in EST. Ki67 labeling index 
illustrated marked reduction after the treatment. 
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Figure 5 Demonstration of the mean value of the intratumoral androgenic enzymes before and 
after the AI treatment grouped by the Ki67 LI response. Error bar represents ±2 standard error of 
measurement (SEM). The significant difference between pre- and post- treatment value was 
displayed with * (P < 0.05). 
 
